Xcout IntelAclaris Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Aclaris Therapeutics, Inc. among biotech companies — ranked by similarity to what Aclaris Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Aclaris Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Aclaris Therapeutics, Inc. at a glance
Aclaris Therapeutics, Inc. is a biotech company headquartered in Wayne, United States. It is publicly listed (ACRS) with a market capitalisation of $807.3M. Xcout tracks 25 named people at Aclaris Therapeutics, Inc., including Hugh Davis (President, Chief Operating Officer & Director).
Aclaris Therapeutics, Inc. leadership
- Hugh DavisPresident, Chief Operating Officer & Director
- Kevin BalthaserChief Financial Officer
- James LoeropChief Business Officer
- Roland KolbeckChief Scientific Officer
- Jesse W. HallChief Medical Officer
- Neal S. WalkerCo-Founder, Chief Executive Officer & Chairman
19 more named people on record for Aclaris Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Aclaris Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Aclaris Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
Confluence Life Sciences, Inc. is a pharmaceutical company based in St. Louis, United States, focused on healthcare and drug development before being acquired by Aclaris Therapeutics.
Biotechnology
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Similar biotech company
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Biotechnology
Q32 Bio Inc. is a clinical-stage biotechnology company, headquartered in Waltham, Massachusetts, focused on creating innovative biologic treatments. Operating within the United States, its primary objective is to re-establish a healthy immune balance in individuals suffering from autoimmune and inflammatory conditions stemming from pathological immune dysfunction. The company's primary therapeutic candidate, ADX-097, is a humanized monoclonal antibody fusion protein engineered to restore proper complement regulation. This compound has successfully concluded its Phase I clinical trial and is being advanced for the treatment of severe renal and other complement-mediated diseases that present significant unmet medical needs. These include specific conditions like lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Furthermore, Q32 Bio is progressing Bempikibart (ADX-914), a fully human monoclonal antibody that functions as an interleukin-7 receptor alpha antagonist. By disrupting the signaling pathways mediated by interleukin-7 and thymic stromal lymphopoietin, Bempikibart aims to normalize adaptive immune function. This promising candidate is currently undergoing Phase II clinical trials for the management of atopic dermatitis and alopecia areata. The company, established in 2017, was previously known as AdMIRx Inc. and rebranded to Q32 Bio Inc. in April 2020.
Biotechnology
Avere Therapeutics is a biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing oral therapies for the treatment of IL-23-driven inflammatory diseases.
Biotechnology
Arcutis Biotherapeutics is a biotechnology company focused on medical dermatology innovation. The company is publicly traded and dedicated to delivering meaningful treatments in the dermatology field.
Similar biotech company
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Similar biotech company
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Similar biotech company
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Similar biotech company
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Biotechnology
Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.
Similar biotech company
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Aclaris Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Aclaris Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →